Aims of management are maintenance of healthy skeletal architecture, through achieving normocalcaemia and limited hyperphosphataemia, and by controlling PTH. Monitoring frequencies etc are biased towards dialysis patients. Less often in pre-dialysis patients and transplant recipients.
Total calcium should be measured every 4-12 weeks and is often approximately corrected by adding 0.02mmol/l for every g/l the serum albumin is below 40g/l. This correction is imperfect in renal failure, but this adjusted calcium can then be used, along with the iPTH taken every six months, to determine tratment according to the calcium algorithm below:
iPTH should be measured initially when GFR drops below 40-50mls/min. At this stage diet should be reviewed for both phosphate and protein content. High PTH levels should lead to introduction of alfacalcidol or calcitriol therapy, Calcium levels permitting. The standard starting dose is 0.25 micrograms (250 nanograms) daily. High iPTH results (eg > 500ng/l) may justify larger doses of calcitriol.
Note that the target range is higher than (2-4x) the normal range, in order to prevent adynamic bone disease resulting from overtreatment.
Alfacalcidol and Calcitriol are equally effective and equipotent. Both should be used at doses of 0.25, 0.5 or 1.0 micrograms for daily oral therapy. If the patient goes outwith the protocol limits, they should be taken out of the protocol and treated separately.
Aluminium should be measured every three months in patients on Al(OH)3. A result of greater than 2.2 micromol/l indicates a high risk of aluminium poisoning and requires cessation of Al (OH3). Levels over 1 should lead to review of therapy.
Serum phosphate (Pi, PO4) should be measured every 4-12 weeks to adjust therapy with phosphate binders. This can be done using the phosphate algorithm below:
For inpatients, prescribe at 8, 12 and 6 and write “with food”. Very approximately, one tablet of each is equivalent, except larger dose size for sevelamer. Download algorithm from the foot of this page.
Calcium carbonate (CaCO3) 500mg chewable tablets is a probably less effective alternative and contains more calcium, but may be useful if patients dislike the calcium acetate formulation.
Aluminium hydroxide (e.g. Alucaps) is an effective binder that is relatively palatable. However it is generally considered less suitable for long-term use because of concerns about aluminium accumulation and toxicity in renal failure, and we now only routinely recommend it for patients on a conservative care or end of life pathway. Monitor Al levels during therapy and be cautious about duration.
Sevelamer is also available as a powder for oral suppression (see algorithm, foot of the page).
Sucroferric Oxyhydroxide one with each meal if sevelamer not tolerated.
Other agents are in development. See also ‘intractable problems’ below.
Phosphate binder type/ dose is decided using measurements of corrected calcium and phosphate (and see above):
Ca >2.6: follow the algorithm above for management of alfacalcidol/calcitriol therapy, and consider changing the alfacalcidol or calcitriol dose.
- If on CaAcetate, consider change to Al(OH)3
- If on non-calcium binders, discuss – review PTH level, other cause
- If intractable and on dialysis, consider lowering dialysate calcium
Ca 2.16 – 2.6
- If on Al(OH)3 change (back) to Ca Acetate (if other factors corrected).
Ca <2.16: follow algorithm above for management of alfacalcidol/ calcitriol therapy. Otherwise/also:
- If already on Ca Acetate and PO4 over 1.5, increase CaAc dose
- If Pi below 1.5, give CaAc between meals as a supplement
Intractable problems with calcium and phosphate
- Compliance is always an important question
Phosphate clearance on dialysis is mainly determined by duration – supplementation may be required with continuous treatments or on daily dialysis
- Parathyroidectomy is usually required at some point in the lifetime of patients who have spent many years on dialysis
- Cinacalcet activates calcium-sensing receptors, leading to reduction of PTH secretion and falls in serum Ca and PO4 through reduced mobilisation from bone. It seems very effective, but is expensive, track record is still relatively short, given the context in which it is used, and its place in long-term therapy has yet to be established.
Parathyroidectomy: management of calcium
Patients with substantial hyperparathyroidism may develop severe hypocalcaemia immediately after parathyroidectomy (“hungry bones”). This is most likely if bone disease is obvious and severe, and may be minimised by pre-administration of alfacalcidol or calcitriol.
- Preop – prescribe alfacalcidol or calcitriol 2-4 micrograms dailys for 3-5 days pre-op, and continued postoperatively until [Ca] is normal. This is safe for 3 days even if [Ca] is high preoperatively.
- Continue usual phosphate binders but stop Cinacalcet
- Make sure you check Ca and PO4 pre-op
- Postop – Measure [Ca] after return from theatre and at 4-8h intervals according to the level and the rate of change. If normal at 48h, further trouble is very unlikely.
- Continue alfacalcidol but keep doubling dose (to max 8-10 micrograms/day) if substantial calcium supplements required.
- If calcium falls below normal (but <1.9) or rapidly, give oral calcium supplements unless symptomatic. Sandocal 1000, 2 tds is a reasonable starting dose. More on calcium supplementation
- If Ca <1.9mmol/l, or if symptomatic, treat with IV calcium: More on calcium supplementation.
- Check [Mg] intermittently if [Ca] is causing trouble
- After discharge – [Ca] should be checked 2-3x/week until stable. (Before dialysis if on HD). Increase alfacalcidol/calcitriol if low or continuing to require calcium supplementation.
UK CKD guidelines – short eCKD guide on management of calcium and phosphate in Stage 3 CKD (stage 4 and advanced problems not included)
Lothian Joint Formulary shared care protocols for prescribing in primary care include sevelamer. LJF home page
Acknowledgements: Neil Turner was the main author for this page. The last modified date is shown in the footer.